These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 18757091)

  • 21. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
    Filipovský J
    Vnitr Lek; 2009 May; 55(5):513-6. PubMed ID: 19514618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
    Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
    Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population.
    Custodis F; Roggenbuck U; Lehmann N; Moebus S; Laufs U; Mahabadi AA; Heusch G; Mann K; Jöckel KH; Erbel R; Böhm M; Möhlenkamp S
    Clin Res Cardiol; 2016 Jul; 105(7):601-12. PubMed ID: 26803646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
    Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
    Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
    Borer JS; Deedwania PC; Kim JB; Böhm M
    Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Janardhanan R; Kenchaiah S; Velazquez EJ; Park Y; McMurray JJ; Weaver WD; Finn PV; White HD; Marin-Neto JA; O'Connor C; Pfeffer MA; Califf RM; Solomon SD;
    Am Heart J; 2006 Jul; 152(1):183-9. PubMed ID: 16824854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study.
    Fosbøl EL; Seibaek M; Brendorp B; Moller DV; Thune JJ; Gislason GH; Torp-Pedersen C; Køber L;
    Int J Cardiol; 2010 Apr; 140(3):279-86. PubMed ID: 19095316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ivabradine in coronary heart disease: experimental and clinical pharmacology].
    Pathak A; Berdeaux A; Mulder P; Thuillez C
    Therapie; 2010; 65(5):483-9. PubMed ID: 21144484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
    Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
    Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.
    Rosa GM; Ferrero S; Ghione P; Valbusa A; Brunelli C
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):279-91. PubMed ID: 24377458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BEAUTIFUL results--the slower, the better?
    Reil JC; Böhm M
    Lancet; 2008 Sep; 372(9641):779-80. PubMed ID: 18757092
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.
    Böhm M; Borer J; Ford I; Gonzalez-Juanatey JR; Komajda M; Lopez-Sendon J; Reil JC; Swedberg K; Tavazzi L
    Clin Res Cardiol; 2013 Jan; 102(1):11-22. PubMed ID: 22575988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R; Ceconi C
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary revascularization for patients with severe left ventricular dysfunction.
    Nagendran J; Norris CM; Graham MM; Ross DB; Macarthur RG; Kieser TM; Maitland AM; Southern D; Meyer SR;
    Ann Thorac Surg; 2013 Dec; 96(6):2038-44. PubMed ID: 23968761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.